EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application

Dominika Myśliwczyk, Małgorzata Myśliwiec, Alina Minarowska iD, Eliza Wasilewska iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188191 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Dominika Myśliwczyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdańsk, 80-210 Gdańsk, Poland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pediatric Obesity, Receptors, Gastrointestinal Hormone, Gastric Inhibitory Polypeptide. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric obesity is a chronic, multifactorial neuroendocrine disease in which disrupted gut–brain signaling, hypothalamic appetite regulation, adipose tissue dysfunction, and altered inter-organ communication sustain positive energy balance. Incretin-based therapies translate this biology into mechanism-based treatment, yet their developmental implications remain incompletely defined. This narrative review integrates evidence on GLP-1 and GIP receptor signaling with pediatric trial data and clinical implementation, with particular attention to developmental modifiers of gut–brain signaling and treatment during growth and puberty. We describe how GLP-1 receptor agonists act across central and peripheral tissues to reduce appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion and examine the rationale for dual GIP/GLP-1 receptor agonism. Randomized pediatric trials demonstrate clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents; however, long-term effects on growth, puberty, bone health, body composition, and weight maintenance remain uncertain. Tirzepatide has shown greater weight-loss efficacy than selective GLP-1 receptor agonism in adults, but no randomized trial has evaluated it in pediatric obesity without diabetes. Incretin-based therapies should be integrated with nutritional, behavioral, psychological, and family-based care. Their future value will depend on durable efficacy, developmental safety, equitable access, and identification of patients most likely to benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsPediatric ObesityReceptors, Gastrointestinal HormoneGastric Inhibitory PolypeptideNeurosecretory SystemsHumansSemaglutideChildGlucagon-Like Peptide-1 ReceptorTirzepatideAnimalsGlucagon-Like PeptidesIncretinsLiraglutide

Stichwörter der Autor:innen

GIP/GLP-1 receptor agonistsGLP-1 receptor agonistsgut–brain axisliraglutideneuroendocrine regulationpediatric obesitysemaglutidetirzepatide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideGlucagon-Like Peptide-1 ReceptorTirzepatideReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGastric Inhibitory PolypeptideGlucagon-Like PeptidesIncretinsLiraglutide

Autor:innen und Institutionen

  • Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
  • Department of Pulmonology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland.
  • Outpatient Cystic Fibrosis Clinic, Department of Pulmonology, Bialystok Medical University Children's Hospital, 15-274 Białystok, Poland.
  • Division of Allergology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.

ORCID-Profile: Alina Minarowska, Eliza Wasilewska

Zitieren

APA

Myśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026). GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188191

Vancouver

Myśliwczyk D, Myśliwiec M, Minarowska A, Wasilewska E. GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188191

BibTeX
@article{Myliwczyk2026,
  author = {Myśliwczyk, Dominika and Myśliwiec, Małgorzata and Minarowska, Alina and Wasilewska, Eliza},
  title = {GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188191}
}
Kostenlos starten →